Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Diploma

(Sharecast News) - Analysts at Berenberg hiked their target price on technical products supplier Diploma from 5,750p to 6,350p on Thursday, stating that it was "one of the highest-quality UK companies". Diploma, a decentralised, value-added distributor of specialist products, focuses on what it calls "small yet critical" components. The nature of the components provided means that Diploma serves customers' opex budgets, not capex budgets, offering "a high degree of insulation" from the economic cycle.

Berenberg noted that Diploma has guided to 5%-plus organic growth per year, operating margins of more than 20% and over 90% free cash flow conversion, with cash proceeds being used to drive further M&A.

"The quality of Diploma's earnings has significantly (and we think structurally) improved in recent years, and the group now sits firmly in the FTSE 100. As such, we think there is merit in comparing Diploma with a peer set of leading global compounders. In light of this evolved peer set, the significant capacity for M&A, and likely upside risk to outer-year organic forecasts, we increase our price target to 6,350p," said Berenberg.

"We forecast Diploma to have leverage of 0.8x net debt/EBITDA at the end of FY25, offering significant firepower for M&A and meaningful upside risk to our forecasts. At the same time, we think an organic recovery in the Seals division will offset the impact of any eventual slowdown in Peerless's momentum."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.